.Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CB02_BarbituratesInCombinatio.BarbituratesInCombinatio

Information

name:BarbituratesInCombinationWithOtherDrugs
ATC code:N05CB02
route:oral
n-compartments1

Barbiturates are central nervous system depressants once used for sedation, anesthesia induction, and management of seizure disorders. Combinations with other agents (such as analgesics or other sedative-hypnotics) were used historically for insomnia, psychiatric indications, or pain relief; however, due to a high risk of dependence, overdose, and drug interactions, these combinations are rarely used or approved today.

Pharmacokinetics

No published population pharmacokinetic study reporting compartmental model parameters for 'barbiturates in combination with other drugs' (ATC N05CB02) could be identified. Estimated parameters below are provided based on typical values for oral barbiturates (such as phenobarbital or amobarbital) in adult, healthy subjects.

References

  1. Eriksson, AS, et al., & Boreus, L (1996). Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 37(8) 769–773. DOI:10.1111/j.1528-1157.1996.tb00650.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/8764817

  2. Schep, LJ, et al., & Mégarbane, B (2012). The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clinical toxicology (Philadelphia, Pa.) 50(6) 458–470. DOI:10.3109/15563650.2012.702218 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22746383

  3. Botha, JH, et al., & Miller, R (1995). A model for estimating individualized valproate clearance values in children. Journal of clinical pharmacology 35(10) 1020–1024. DOI:10.1002/j.1552-4604.1995.tb04020.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/8568010

Revisions


Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos